Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center M.D. Anderson Cancer Center joins ongoing Phase I/II clinical trial and enters into research collaboration with Stemline

NEW YORK, Nov. 30 /PRNewswire/ -- Stemline Therapeutics, Inc., a private clinical stage biopharmaceutical company and leading developer of oncology compounds directed to cancer stem cells, today announced that The University of Texas M.D. Anderson Cancer Center (Houston, TX) and Stemline have entered into a research collaboration. As part of this collaboration, M.D. Anderson has joined an ongoing Phase I/II clinical trial of SL-401 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

"We are pleased to be involved with Stemline and its innovative programs targeting cancer stem cells," said Hagop Kantarjian, MD, Chairman of the Department of Leukemia at M.D. Anderson. "This clinical trial provides a new option for our patients with AML and MDS."

Stemline's CEO, Ivan Bergstein, MD, said. "We are very pleased to have M.D. Anderson, a world class institution and leader in oncology, join the ongoing Phase I/II study in AML and MDS for SL-401 and work with us on additional programs. This is an exciting time for the company as we expand our clinical program, advance our diverse pipeline, and continue to build out our proprietary platforms."

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor which is expressed on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I/II clinical trial. Stemline is also developing a proprietary portfolio of biological and small molecule compounds directed at high value cancer stem cell targets of a variety of hematological and solid cancers. Stemline has built a robust discovery platform called StemScreen® which the Company has utilized to identify candidate compounds that target cancer stem cells. For more information, please visit the Company's website at www.stemline.com.



Stemline Contact:
Tom Cirrito, PhD
Director of Operations
Stemline Therapeutics, Inc.
Tel: 212-531-5976
Email: tcirrito@stemline.com


SOURCE Stemline Therapeutics, Inc



RELATED LINKS
http://www.stemline.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.